Follow-up surveillance of muscle-invasive urinary bladder cancer after curative treatment

被引:1
|
作者
Schulz, G. B. [1 ]
Stief, C. G. [1 ]
Schlenker, B. [1 ]
机构
[1] Klinikum Ludwig Maximilians Univ LMU Munchen, Urol Klin & Poliklin, Campus Grosshadern,Marchioninistr 15, D-81377 Munich, Germany
来源
UROLOGE | 2019年 / 58卷 / 09期
关键词
Urinary bladder neoplasms; Tumor surveillance; Urothelial carcinoma; Tumor recurrence; Urine cytology; RADICAL CYSTECTOMY; UROTHELIAL CARCINOMA; URETHRAL RECURRENCE; TRACT RECURRENCE; RISK-FACTORS; REMNANT UROTHELIUM; TUMOR RECURRENCE; OUTCOMES; DIVERSION; SURVIVAL;
D O I
10.1007/s00120-019-1012-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Follow-up care of patients with muscle-invasive bladder cancer is subdivided into oncological and functional surveillance. More than 80% of local relapses and distant metastases occur within the first 2 years. Recurrences in the remnant urothelium also occur several years after radical cystectomy. Urinary cytology and a computed tomography (CT) scan of the abdomen and thorax including a urography phase are the standard diagnostics for tumor follow-up. There is no clear evidence for a survival benefit for the detection of asymptomatic vs. symptomatic recurrences. After partial cystectomy or trimodal treatment, there is no established follow-up schedule; however, the relatively high incidence of intravesical recurrences should be considered as there are curative treatment approaches including salvage cystectomy. Functional surveillance, which should be carried out lifelong, encompasses prevention and diagnostics of metabolic complications, urethral/ureteral strictures, problems with the urinary stoma, urinary incontinence, sexual dysfunction and urinary tract infections.
引用
收藏
页码:1093 / 1106
页数:14
相关论文
共 50 条
  • [31] Rational follow-up of non-muscle invasive bladder cancer
    von Landenberg, N.
    Benderska-Soeder, N.
    Bismarck, E.
    Kernig, K.
    Erne, E.
    Goebell, P. J.
    Schmitz-Draeger, B. J.
    UROLOGE, 2021, 60 (11): : 1409 - 1415
  • [32] Selective bladder preservation with curative intent for muscle-invasive bladder cancer: A contemporary review
    Koga, Fumitaka
    Kihara, Kazunori
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (05) : 388 - 401
  • [33] Efficacy of curative radiotherapy for the treatment of elderly patients with muscle-invasive bladder cancer: a systematic review
    Sakaguchi, Masakuni
    Maebayashi, Toshiya
    Sekino, Yuta
    Ishikawa, Hitoshi
    BMC UROLOGY, 2025, 25 (01):
  • [34] Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics
    Schiffer, Eric
    Vlahou, Antonia
    Petrolekas, Andreas
    Stravodimos, Konstantinos
    Tauber, Robert
    Geschwend, Juergen E.
    Neuhaus, Jochen
    Stolzenburg, Jens-Uwe
    Conaway, Mark R.
    Mischak, Harald
    Theodorescu, Dan
    CLINICAL CANCER RESEARCH, 2009, 15 (15) : 4935 - 4943
  • [35] Muscle-invasive bladder cancer
    Kuebler, H.
    Gschwend, J. E.
    ONKOLOGE, 2012, 18 (11): : 977 - +
  • [36] Muscle-Invasive Bladder Cancer
    Hasan, Shaakir
    Chhabra, Arpit M.
    Choi, J. Isabelle
    Simone, Charles B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : 309 - 310
  • [37] Muscle-invasive bladder cancer
    Buchler, Jakob
    Gschwend, Juergen E.
    Retz, Margitta
    Schmid, Sebastian C.
    UROLOGE, 2021, 60 (06): : 769 - 775
  • [38] POSSIBILITIES AND LIMITS OF THE CURATIVE AND PALLIATIVE THERAPY OF MUSCLE-INVASIVE CARCINOMAS OF THE URINARY-BLADDER
    HOFMANN, W
    LANGKOPF, B
    ZEITSCHRIFT FUR UROLOGIE UND NEPHROLOGIE, 1987, 80 (07): : 413 - 424
  • [39] FOLLOW-UP OF THE PATIENT AFTER CURATIVE TREATMENT
    Westeel, V.
    LUNG CANCER, 2011, 71 : S10 - S11
  • [40] Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer
    Zuiverloon, Tahlita C. M.
    Theodorescu, Dan
    PHARMACOGENOMICS, 2017, 18 (12) : 1167 - 1178